Nick Ray Appointed as Chief Scientific Officer

RNS Number : 1531M

C4X Discovery Holdings PLC

10 January 2023

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

C4XD Appoints Nick Ray as Chief Scientific Officer

10 January 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces the appointment of Nick Ray, PhD, as Chief Scientific Officer with immediate effect. 

Nick, a medicinal chemist by training who joined C4XD in 2016, is currently Senior Vice President Drug Discovery, leading the medicinal chemistry, structural analysis and computational chemistry/cheminformatics teams.  Nick will continue to work closely with Clare Murray PhD, SVP Drug Discovery, to advance the C4XD Drug Discovery portfolio from target selection through to pre-clinical candidate generation and partnering, and with CTO, Charles Blundell PhD, to continue development of our conformational analysis technology, 4Sight.

Nick has more than 30 years' experience leading key programmes at large multi-national companies including Rhône-Poulenc, Celltech and Argenta/Charles River, in the therapeutic areas of oncology, respiratory diseases, inflammation, CNS, pain and metabolic diseases.  Eight of these programmes have progressed into the clinic to date. As head of the chemistry department at Charles River's Harlow U.K. site, Nick was responsible for more than 70 chemists, fostering both the importance of strong medicinal and synthetic chemistry skills and championing professional development for his team, winning the Royal Society of Chemistry Retrosynthesis competition in 2015.  He is a named inventor on over 75 patents and patent applications and has published 21 papers and presentation abstracts.  Nick holds a PhD in organic chemistry from the University of Birmingham, UK.

Clive Dix, CEO of C4XD, said: "Nick has played a key role in the growth of C4XD and its reputation as a leading Drug Discovery company.  Since joining the Company in 2016, his in-depth scientific expertise, particularly in medicinal and computational chemistry, has enabled C4XD to develop a growing portfolio of high quality small molecule Drug Discovery programmes, the very core of our business.  Nick is highly respected both within C4XD and across our industry, and more recently, he has made a significant contribution to the commercial side of the business with the successful partnering of our IL-17A Inhibitor programme with Sanofi and our NRF2 Activator programme with AstraZeneca.  We are delighted to announce his promotion to Chief Scientific Officer."

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have three commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For further information see www.c4xdiscovery.com

 

END

 

 

MSCEAXFNEAPDEFA